A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient.

ABSTRACT: Lung cancer is the leading cause of cancer-related mortality worldwide. Patients with locally advanced non-small cell lung cancer (NSCLC) have lower overall survival. Studies have shown that some patients with unresectable stage III NSCLC develop disease progression after initial chemoradiotherapy, and new treatment is needed to improve the prognosis of these patients. The rapid development of therapy has greatly changed and continued to renew the treatment strategy of advanced NSCLC. However, the clinical treatment for patients with the wild-type gene remains problematic, and chemotherapy with platinum are not yet considered satisfactory. Herein, we are reporting a case of a patient with wild-type gene mutation locally advanced NSCLC who was treated with neoadjuvant therapy by using combi

SUBMITTER: Gao P 

PROVIDER: S-EPMC7653127 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature